Mithra Pharmaceuticals SA

ENXTBR:MITRA Stock Report

Market Cap: €14.9m

Mithra Pharmaceuticals Future Growth

Future criteria checks 5/6

Mithra Pharmaceuticals is forecast to grow earnings and revenue by 100.7% and 43.1% per annum respectively.

Key information

100.7%

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth14.5%
Revenue growth rate43.1%
Future return on equityn/a
Analyst coverage

Low

Last updated06 May 2024

Recent future growth updates

Recent updates

Not Many Are Piling Into Mithra Pharmaceuticals SA (EBR:MITRA) Stock Yet As It Plummets 26%

Apr 06
Not Many Are Piling Into Mithra Pharmaceuticals SA (EBR:MITRA) Stock Yet As It Plummets 26%

Revenues Working Against Mithra Pharmaceuticals SA's (EBR:MITRA) Share Price Following 39% Dive

Feb 07
Revenues Working Against Mithra Pharmaceuticals SA's (EBR:MITRA) Share Price Following 39% Dive

Party Time: Brokers Just Made Major Increases To Their Mithra Pharmaceuticals SA (EBR:MITRA) Earnings Forecasts

Nov 09
Party Time: Brokers Just Made Major Increases To Their Mithra Pharmaceuticals SA (EBR:MITRA) Earnings Forecasts

These Analysts Just Made A Huge Downgrade To Their Mithra Pharmaceuticals SA (EBR:MITRA) EPS Forecasts

Oct 05
These Analysts Just Made A Huge Downgrade To Their Mithra Pharmaceuticals SA (EBR:MITRA) EPS Forecasts

Take Care Before Diving Into The Deep End On Mithra Pharmaceuticals SA (EBR:MITRA)

May 23
Take Care Before Diving Into The Deep End On Mithra Pharmaceuticals SA (EBR:MITRA)

Bullish: Analysts Just Made A Huge Upgrade To Their Mithra Pharmaceuticals SA (EBR:MITRA) Forecasts

Aug 11
Bullish: Analysts Just Made A Huge Upgrade To Their Mithra Pharmaceuticals SA (EBR:MITRA) Forecasts

Growth Investors: Industry Analysts Just Upgraded Their Mithra Pharmaceuticals SA (EBR:MITRA) Revenue Forecasts By 21%

Mar 13
Growth Investors: Industry Analysts Just Upgraded Their Mithra Pharmaceuticals SA (EBR:MITRA) Revenue Forecasts By 21%

Mithra Pharmaceuticals (EBR:MITRA) Is Making Moderate Use Of Debt

Dec 22
Mithra Pharmaceuticals (EBR:MITRA) Is Making Moderate Use Of Debt

Some Mithra Pharmaceuticals SA (EBR:MITRA) Analysts Just Made A Major Cut To Next Year's Estimates

Nov 24
Some Mithra Pharmaceuticals SA (EBR:MITRA) Analysts Just Made A Major Cut To Next Year's Estimates

Here's Why Mithra Pharmaceuticals (EBR:MITRA) Can Afford Some Debt

Jun 07
Here's Why Mithra Pharmaceuticals (EBR:MITRA) Can Afford Some Debt

When Will Mithra Pharmaceuticals SA (EBR:MITRA) Turn A Profit?

May 10
When Will Mithra Pharmaceuticals SA (EBR:MITRA) Turn A Profit?

Is Mithra Pharmaceuticals SA's (EBR:MITRA) Shareholder Ownership Skewed Towards Insiders?

Mar 18
Is Mithra Pharmaceuticals SA's (EBR:MITRA) Shareholder Ownership Skewed Towards Insiders?

We're Not So Sure You Should Rely on Mithra Pharmaceuticals' (EBR:MITRA) Statutory Earnings

Feb 16
We're Not So Sure You Should Rely on Mithra Pharmaceuticals' (EBR:MITRA) Statutory Earnings

Analysts Expect Breakeven For Mithra Pharmaceuticals SA (EBR:MITRA) Before Long

Jan 21
Analysts Expect Breakeven For Mithra Pharmaceuticals SA (EBR:MITRA) Before Long

Some Mithra Pharmaceuticals SA (EBR:MITRA) Analysts Just Made A Major Cut To Next Year's Estimates

Nov 29
Some Mithra Pharmaceuticals SA (EBR:MITRA) Analysts Just Made A Major Cut To Next Year's Estimates

Earnings and Revenue Growth Forecasts

ENXTBR:MITRA - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202613744N/AN/A1
12/31/2025961450601
12/31/202444-55-26-161
12/31/202340-174-2-2N/A
9/30/202351-126-15-6N/A
6/30/202363-79-28-9N/A
3/31/202365-69-55-33N/A
12/31/202267-60-82-57N/A
9/30/202244-76-92-68N/A
6/30/202222-93-102-78N/A
3/31/202222-105-100-78N/A
12/31/202123-117-98-77N/A
9/30/202121-115-94-75N/A
6/30/202119-113-91-73N/A
3/31/202114-103-94-77N/A
12/31/20209-92-96-80N/A
9/30/202044-31-85-70N/A
6/30/20207929-73-59N/A
3/31/2020881-68-53N/A
12/31/201997-27-62-47N/A
9/30/201984-54-42-28N/A
6/30/201971-82-21-5N/A
3/31/201964-55-14-1N/A
12/31/201858-28-74N/A
9/30/201846-41-23-9N/A
6/30/201833-53-40-25N/A
3/31/201833-46-44-28N/A
12/31/201732-38-47-31N/A
9/30/201726-37N/A-32N/A
6/30/201720-36N/A-32N/A
3/31/201721-36N/A-28N/A
12/31/201622-35N/A-23N/A
9/30/201621-29N/A-23N/A
6/30/201620-23N/A-22N/A
3/31/201620-16N/A-20N/A
12/31/201520-10N/A-18N/A
9/30/201519-9N/A-15N/A
6/30/201518-8N/A-12N/A
3/31/201519-5N/A-6N/A
12/31/201419-3N/A-1N/A
12/31/201318-2N/A1N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MITRA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.1%).

Earnings vs Market: MITRA is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MITRA is expected to become profitable in the next 3 years.

Revenue vs Market: MITRA's revenue (43.1% per year) is forecast to grow faster than the Belgian market (6.5% per year).

High Growth Revenue: MITRA's revenue (43.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MITRA's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.